What does D5-PHARMA do?

D5-PHARMA is a logistics company in Ganshoren. Private Limited, started on 27 February 2003, 1 establishment.

What is the address of D5-PHARMA?

The registered office of D5-PHARMA is located at Jetteselaan 295, 1083 Ganshoren.

Is D5-PHARMA still active?

Yes. According to the CBE (31 October 2026) D5-PHARMA is active, legal situation “Normale toestand”, started on 27 February 2003.

Is D5-PHARMA registered on Peppol?

Yes, D5-PHARMA is registered on the Peppol network with ID 0208:0479659456.

What is the enterprise number of D5-PHARMA?

The enterprise number of D5-PHARMA is BE0479659456.

When was D5-PHARMA founded?

D5-PHARMA was founded on 27 February 2003.

Who are the directors of D5-PHARMA?

According to the 2025 annual accounts, the directors of D5-PHARMA are: AGANJU HOLDING SRL.

Is D5-PHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 27 February 2003; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did D5-PHARMA make in 2025?

D5-PHARMA posted a profit after taxes of € 26,472 in financial year 2025.

What is the revenue of D5-PHARMA?

As a small company, D5-PHARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 299,257.

How much does an employee at D5-PHARMA earn?

The average wage cost per full-time employee at D5-PHARMA was € 62,000 in 2025: staff costs of € 185,970 for 3 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does D5-PHARMA have?

According to the 2025 annual accounts, D5-PHARMA has 3 full-time equivalents (FTE).

D5-PHARMA (Private Limited) - Ganshoren - BE0479659456

Dossier D5-PHARMA, printed on 31 October 2026 from databakkes.be/en/0479659456/d5-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

D5-PHARMA from Ganshoren, company number BE0479659456, closed financial year 2025 with a result of € 26,472 after tax. For that financial year D5-PHARMA recorded a gross margin of € 299,257 and equity of € 115,485. Compared with financial year 2024, the result moved from € -65,894 to € 26,472. Profitable, and profit is growing. The company holds a healthy buffer. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on August 31, 2026.

What it is worth Healthy

€ 115,485

▼ 46% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 26,472

▲ still € 65,894 loss in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 55,962

▲ 148% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 125,000 paid out

More than the year’s profit went to the shareholders; reserves fell.

People and assets in 2025

Full-time equivalents

▼ 0.2 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 185,970

▼ 3% vs 2024

€ 62,000 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 1,718

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 9 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 632,096

▼ 9% vs 2024

€ 66,837 is repaid this year. At this pace the long-term loan is gone in ≈ 9 years.

Owed to suppliers

€ 588,481

▲ 2% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Wages and social charges

€ 25,110

▼ 39% vs 2024

Wages, holiday pay and social contributions still to pay. No outstanding taxes.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 244,285 Gross margin 2022: € 244,285 First fiscal year in the series	€ 203,575 Gross margin 2023: € 203,575 ▼ 17% vs 2022 (€ 244,285) Unfavourable step	€ 207,944 Gross margin 2024: € 207,944 ▲ 2% vs 2023 (€ 203,575) Favourable step	€ 299,257 Gross margin 2025: € 299,257 ▲ 44% vs 2024 (€ 207,944) Favourable step	▲ 44%
Profit after taxes	€ 53,762 Profit after taxes 2022: € 53,762 First fiscal year in the series	€ -47,388 Profit after taxes 2023: € -47,388 ▼ € 101,150 vs 2022 (€ 53,762) Unfavourable step	€ -65,894 Profit after taxes 2024: € -65,894 ▼ € 18,506 vs 2023 (€ -47,388) Unfavourable step	€ 26,472 Profit after taxes 2025: € 26,472 ▲ € 92,366 vs 2024 (€ -65,894) Favourable step	▲ € 92,366
Equity	€ 427,295 Equity 2022: € 427,295 First fiscal year in the series	€ 379,908 Equity 2023: € 379,908 ▼ 11% vs 2022 (€ 427,295) Unfavourable step	€ 214,013 Equity 2024: € 214,013 ▼ 44% vs 2023 (€ 379,908) Unfavourable step	€ 115,485 Equity 2025: € 115,485 ▼ 46% vs 2024 (€ 214,013) Unfavourable step	▼ 46%
Total debts	€ 51,914 Total debts 2022: € 51,914 First fiscal year in the series	€ 1,187,240 Total debts 2023: € 1,187,240 ▲ € 1.1 million vs 2022 (€ 51,914) Unfavourable step	€ 1,412,457 Total debts 2024: € 1,412,457 ▲ 19% vs 2023 (€ 1,187,240) Unfavourable step	€ 1,370,687 Total debts 2025: € 1,370,687 ▼ 3% vs 2024 (€ 1,412,457) Favourable step	▼ 3%
Cash	€ 317,675 Cash 2022: € 317,675 First fiscal year in the series	€ 51,732 Cash 2023: € 51,732 ▼ 84% vs 2022 (€ 317,675) Unfavourable step	€ 22,604 Cash 2024: € 22,604 ▼ 56% vs 2023 (€ 51,732) Unfavourable step	€ 55,962 Cash 2025: € 55,962 ▲ 148% vs 2024 (€ 22,604) Favourable step	▲ 148%
Land & buildings	-	€ 542,912 Land & buildings 2023: € 542,912 First fiscal year in the series	€ 514,911 Land & buildings 2024: € 514,911 ▼ 5% vs 2023 (€ 542,912) Unchanged	€ 486,910 Land & buildings 2025: € 486,910 ▼ 5% vs 2024 (€ 514,911) Unchanged	▼ 5%
Retained profit	€ 421,095 Retained profit 2022: € 421,095 First fiscal year in the series	€ 373,708 Retained profit 2023: € 373,708 ▼ 11% vs 2022 (€ 421,095) Unfavourable step	€ 207,813 Retained profit 2024: € 207,813 ▼ 44% vs 2023 (€ 373,708) Unfavourable step	€ 109,285 Retained profit 2025: € 109,285 ▼ 47% vs 2024 (€ 207,813) Unfavourable step	▼ 47%
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 0 Dividend 2023: € 0 Unchanged (€ 0) Unchanged	€ 100,000 Dividend 2024: € 100,000 Unchanged (€ 0) Unchanged	€ 125,000 Dividend 2025: € 125,000 ▲ 25% vs 2024 (€ 100,000) Unchanged	▲ 25%
Bank debt	€ 8,179 Bank debt 2022: € 8,179 First fiscal year in the series	€ 767,320 Bank debt 2023: € 767,320 ▲ € 759,141 vs 2022 (€ 8,179) Unfavourable step	€ 696,224 Bank debt 2024: € 696,224 ▼ 9% vs 2023 (€ 767,320) Favourable step	€ 632,096 Bank debt 2025: € 632,096 ▼ 9% vs 2024 (€ 696,224) Favourable step	▼ 9%
Balance sheet total	€ 479,210 Balance sheet total 2022: € 479,210 First fiscal year in the series	€ 1,567,148 Balance sheet total 2023: € 1,567,148 ▲ 227% vs 2022 (€ 479,210) Unchanged	€ 1,626,470 Balance sheet total 2024: € 1,626,470 ▲ 4% vs 2023 (€ 1,567,148) Unchanged	€ 1,486,172 Balance sheet total 2025: € 1,486,172 ▼ 9% vs 2024 (€ 1,626,470) Unchanged	▼ 9%
Employees (FTE)	2.3 Employees (FTE) 2022: 2.3 First fiscal year in the series	1.7 Employees (FTE) 2023: 1.7 ▼ 0.6 vs 2022 (2.3) Unchanged	3.2 Employees (FTE) 2024: 3.2 ▲ 1.5 vs 2023 (1.7) Unchanged	3 Employees (FTE) 2025: 3 ▼ 0.2 vs 2024 (3.2) Unchanged	▼ 0.2

Key figures of D5-PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to D5-PHARMA?

What happened at D5-PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 31, 2026 New annual accounts for financial year 2025: profit of € 26,472. filed late Source: NBB ↗
Mar 31, 2003 New establishment in Ganshoren. KBO
Feb 27, 2003 Start of the company according to the CBE. KBO

In short

From € 53,762 profit in 2022 to € 26,472 profit in 2025.

Paid € 14,813 in corporate taxes since 2022.

Best year ever: 2022, with € 53,762 profit.

On average € 99,800 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

AGANJU HOLDING 100%

The stake of AGANJU HOLDING comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

D5-PHARMA

Behind D5-PHARMA is AGANJU HOLDING SRL. The shares are held by AGANJU HOLDING (100%).

Directors

According to the 2025 annual accounts

AGANJU HOLDING SRL

Managing director · represented by HAMIAFO NGATCHI HERVE

Also active at: AGANJU CONCEPT, PHARMACIE DES ARCHIDUCS, D4-PHARMA, CENTRE MEDICAL DEWAND, PHARMACIE DU ROOSENDAEL

Shareholders

AGANJU HOLDING

100%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Jetteselaan 295

1083 Ganshoren

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0479.659.456

VAT number

BE 0479.659.456

Registered office

Jetteselaan 295, 1083 Ganshoren

Names & denominations

D5-PHARMA

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

27 February 2003

Peppol

Active · Active since 12 Dec 2025

Activities · NACE

Apothekers

Detailhandel in farmaceutische producten

View on CBE Public ↗ Annual accounts (NBB) ↗

D5-PHARMA

Financials

What happened to D5-PHARMA?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Details

Frequently asked questions